KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Liabilities: 2011-2025

Historic Other Non-Current Liabilities for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $5.9 million.

  • Travere Therapeutics' Other Non-Current Liabilities fell 63.61% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 63.61%. This contributed to the annual value of $6.8 million for FY2024, which is 34.15% down from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Other Non-Current Liabilities is $5.9 million, which was down 24.79% from $7.9 million recorded in Q2 2025.
  • Travere Therapeutics' Other Non-Current Liabilities' 5-year high stood at $76.2 million during Q3 2022, with a 5-year trough of $5.9 million in Q3 2025.
  • Its 3-year average for Other Non-Current Liabilities is $22.3 million, with a median of $10.3 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first spiked by 224.27% in 2021, then crashed by 89.00% in 2023.
  • Over the past 5 years, Travere Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $67.1 million in 2021, then slumped by 86.01% to $9.4 million in 2022, then rose by 9.96% to $10.3 million in 2023, then slumped by 34.15% to $6.8 million in 2024, then tumbled by 63.61% to $5.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $5.9 million for Q3 2025, versus $7.9 million for Q2 2025 and $7.3 million for Q1 2025.